European Journal of Clinical Pharmacology

Papers
(The H4-Index of European Journal of Clinical Pharmacology is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Therapeutic drug monitoring of oral targeted antineoplastic drugs111
Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies77
What about COVID-19 and arachidonic acid pathway?58
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-257
Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review45
Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review44
Global prevalence and types of complementary and alternative medicines use amongst adults with diabetes: systematic review and meta-analysis41
Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects39
Coenzyme Q10 supplementation and oxidative stress parameters: a systematic review and meta-analysis of clinical trials34
Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dem33
A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK932
Ivy leaf (Hedera helix) for acute upper respiratory tract infections: an updated systematic review29
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis28
Drug prescriptions in nursing home residents: an Italian multicenter observational study27
Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review26
Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials26
Can iron chelation as an adjunct treatment of COVID-19 improve the clinical outcome?25
Safety and efficacy of tolcapone in Parkinson’s disease: systematic review24
Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district24
Essentials in saline pharmacology for nasal or respiratory hygiene in times of COVID-1924
Pharmacokinetics and pharmacodynamics of intranasal remimazolam—a randomized controlled clinical trial24
Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients22
Tocilizumab for treating COVID-19: a systemic review and meta-analysis of retrospective studies22
0.055351972579956